Post by
Viking2233 on Jun 24, 2023 12:46pm
Big Week Ahead
Well we are down crunch time here. Management is under the microscope here. They told the markets that phase 2 independent data review would be out before the end of 1st half 2023. So will management deliver as promised, their credibility is on the line. Will the data be positive enough for Raymond James analyst to move from speculative buy at $3.50 per share to a strong buy with $10 target.
Next week we are due for a major catalyst, if management delivers we could have a major short squeeze, if they fail to deliver as promised the shorts will continue to take charge with new 52 week lows coming.
I have not had a position for a long time, only a few months but have been following for a few years. This is a pivotal week ahead and I am mildly optimistic that phase 2 data will be released. The fact that Fed Government gave them $4M recently and that they were approved for Catco Phase 3 trial tells me the data should be stellar. It has been over 500 days with no material update so there should be no excuses here. Its time to deliver and time for ARCH to take the next step forward and get a market cap valuation close to its similar stage peers in the $800M to $1.5B range not the $120M market cap they currently have.